Literature DB >> 3602953

Cutaneous fibrinolytic activity in primary hypertrophic osteoarthropathy.

M Matucci-Cerinic, T Lotti, I Jajic, S Di Lollo, L Brunetti, D Orlic.   

Abstract

Cutaneous fibrinolytic activity was investigated in 13 patients affected with Primary Hypertrophic Osteoarthropathy in the advanced phase. Biopsies were taken from periungueal skin of the ippocratic finger and from the dorsum of the first phalanx: cutaneous fibrinolytic activity was investigated with Todd's autohistographic method as modified by Lotti et al., showing increased activity in periungueal skin (10/13) and normal in the apparently uninvolved skin (9/13). We suggest that the increase in plasminogen activator activity, in the advanced phase of the disease, may be related to the increased growth of the connective tissue that is characteristic of the disease.

Entities:  

Mesh:

Year:  1987        PMID: 3602953     DOI: 10.3109/03009748709165275

Source DB:  PubMed          Journal:  Scand J Rheumatol        ISSN: 0300-9742            Impact factor:   3.641


  4 in total

1.  Bone abnormalities and severe arthritis in pachydermoperiostosis.

Authors:  R G Cooper; A J Freemont; M Riley; P J Holt; D C Anderson; M I Jayson
Journal:  Ann Rheum Dis       Date:  1992-03       Impact factor: 19.103

2.  Hypertrophic osteoarthropathy: endothelium and platelet function.

Authors:  F Silveri; R De Angelis; F Argentati; D Brecciaroli; S Muti; C Cervini
Journal:  Clin Rheumatol       Date:  1996-09       Impact factor: 2.980

3.  Colchicine treatment in a case of pachydermoperiostosis with acroosteolysis.

Authors:  M Matucci-Cerinic; L Fattorini; G Gerini; A Lombardi; A Pignone; N Petrini; T Lotti
Journal:  Rheumatol Int       Date:  1988       Impact factor: 2.631

4.  Pachydermoperiostosis (primary hypertrophic osteoarthropathy): report of a case with evidence of endothelial and connective tissue involvement.

Authors:  M Matucci-Cerinic; S Cinti; M Morroni; T Lotti; G Nuzzaci; E Lucente; S di Lollo; M Ceruso; M Cagnoni
Journal:  Ann Rheum Dis       Date:  1989-03       Impact factor: 19.103

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.